Apixaban (Eliquis) for Stroke Prevention in Atrial Fibrillation | AAFP
Peripheral Matters | Dose-Reduced Direct Oral Anticoagulants: Practical Considerations - American College of Cardiology
Cureus | Expert Opinion on the Use of Novel Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation for the Primary Care Setting in India: A Literature Review | Article
Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation | Journal of the American College of Cardiology
The use of ELIQUIS® (apixaban) in various clinical populations - ppt download
Dose reduction criteria for NOACs | Download Scientific Diagram
Target-Specific Oral Anticoagulants
ELIQUIS® (apixaban) dosing for NVAF patients | ELIQUIS UK
Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation | Scientific Reports
Table 1 from Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial - ScienceDirect
Frontiers | Efficacy and Safety of Non-recommended Dose of New Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study - Staerk - 2018 - Journal of Internal Medicine - Wiley Online Library
Dose reduction criteria of NOACs 18 | Download Scientific Diagram
Eliquis Full Prescribing Information, Dosage & Side Effects | MIMS Malaysia
The use of direct oral anticoagulants in chronic kidney disease - Parker - 2018 - British Journal of Haematology - Wiley Online Library